InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
September 09 2021 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a
research and clinical-stage biomaterials and biotechnology company
with a focus on the treatment of spinal cord injuries, today
announced that Richard Toselli, M.D., President and Chief Executive
Officer, will present at the upcoming H.C. Wainwright Annual Global
Investment Conference, which runs from September 13 – 15, 2021. The
conference will be held in a virtual format.
A webcast of Dr. Toselli’s presentation will be available on the
Investor Relations - Events section of the company website at
https://investors.invivotherapeutics.com/events, beginning
September 13, 2021 at 7:00 am ET. Dr. Toselli and company
management will also be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005089/en/
Investors: Bret Shapiro, Managing Partner CORE IR
brets@coreir.com (516) 222-2560
Media Gina Nugent Ten Bridge Communications
gina@tenbridgecommunications.com 617-460-3579
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024